Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
PLoS Negl Trop Dis ; 7(5): e2191, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23658847

RESUMO

Buruli ulcer (BU), caused by Mycobacterium ulcerans is a chronic necrotizing skin disease. It usually starts with a subcutaneous nodule or plaque containing large clusters of extracellular acid-fast bacilli. Surrounding tissue is destroyed by the cytotoxic macrolide toxin mycolactone produced by microcolonies of M. ulcerans. Skin covering the destroyed subcutaneous fat and soft tissue may eventually break down leading to the formation of large ulcers that progress, if untreated, over months and years. Here we have analyzed the bacterial flora of BU lesions of three different groups of patients before, during and after daily treatment with streptomycin and rifampicin for eight weeks (SR8) and determined drug resistance of the bacteria isolated from the lesions. Before SR8 treatment, more than 60% of the examined BU lesions were infected with other bacteria, with Staphylococcus aureus and Pseudomonas aeruginosa being the most prominent ones. During treatment, 65% of all lesions were still infected, mainly with P. aeruginosa. After completion of SR8 treatment, still more than 75% of lesions clinically suspected to be infected were microbiologically confirmed as infected, mainly with P. aeruginosa or Proteus miriabilis. Drug susceptibility tests revealed especially for S. aureus a high frequency of resistance to the first line drugs used in Ghana. Our results show that secondary infection of BU lesions is common. This could lead to delayed healing and should therefore be further investigated.


Assuntos
Antibacterianos/uso terapêutico , Úlcera de Buruli/complicações , Úlcera de Buruli/tratamento farmacológico , Rifampina/uso terapêutico , Estreptomicina/uso terapêutico , Infecção dos Ferimentos/epidemiologia , Infecção dos Ferimentos/microbiologia , Adolescente , Adulto , Idoso , Bactérias/classificação , Bactérias/efeitos dos fármacos , Bactérias/isolamento & purificação , Criança , Pré-Escolar , Coinfecção/epidemiologia , Coinfecção/microbiologia , Farmacorresistência Bacteriana , Feminino , Gana , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
2.
PLoS Negl Trop Dis ; 6(1): e1460, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22253937

RESUMO

BACKGROUND: Previous analyses of sera from a limited number of Ghanaian Buruli ulcer (BU) patients, their household contacts, individuals living in BU non-endemic regions as well as European controls have indicated that antibody responses to the M. ulcerans 18 kDa small heat shock protein (shsp) reflect exposure to this pathogen. Here, we have investigated to what extent inhabitants of regions in Ghana regarded as non-endemic for BU develop anti-18 kDa shsp antibody titers. METHODOLOGY/PRINCIPAL FINDINGS: For this purpose we determined anti-18 kDa shsp IgG titers in sera collected from healthy inhabitants of the BU endemic Densu River Valley and the Volta Region, which was so far regarded as BU non-endemic. Significantly more sera from the Densu River Valley contained anti-18 kDa shsp IgG (32% versus 12%, respectively). However, some sera from the Volta Region also showed high titers. When interviewing these sero-responders, it was revealed that the person with the highest titer had a chronic wound, which was clinically diagnosed and laboratory reconfirmed as active BU. After identification of this BU index case, further BU cases were clinically diagnosed by the Volta Region local health authorities and laboratory reconfirmed. Interestingly, there was neither a difference in sero-prevalence nor in IS2404 PCR positivity of environmental samples between BU endemic and non-endemic communities located in the Densu River Valley. CONCLUSIONS: These data indicate that the intensity of exposure to M. ulcerans in endemic and non-endemic communities along the Densu River is comparable and that currently unknown host and/or pathogen factors may determine how frequently exposure is leading to clinical disease. While even high serum titers of anti-18 kDa shsp IgG do not indicate active disease, sero-epidemiological studies can be used to identify new BU endemic areas.


Assuntos
Anticorpos Antibacterianos/sangue , Úlcera de Buruli/epidemiologia , Mycobacterium ulcerans/imunologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos de Bactérias , Criança , Pré-Escolar , Feminino , Gana/epidemiologia , Humanos , Imunoglobulina G/sangue , Masculino , Pessoa de Meia-Idade , Estudos Soroepidemiológicos , Testes Sorológicos/métodos , Adulto Jovem
3.
Am J Trop Med Hyg ; 85(5): 900-4, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22049046

RESUMO

The introduction of antibiotic therapy as first-line treatment of Buruli ulcer underlines the importance of laboratory confirmation of clinical diagnosis. Because smear microscopy has very limited sensitivity, the technically demanding and more expensive IS2404 diagnostic polymerase chain reaction (PCR) has become the main method for confirmation. By optimization of the release of mycobacteria from swab specimen and concentration of bacterial suspensions before smearing, we were able to improve the detection rate of acid-fast bacilli by microscopy after Ziehl-Neelsen staining. Compared with IS2404 PCR, which is the gold standard diagnostic method, the sensitivity and specificity of microscopy with 100 concentrated specimens were 58.4% and 95.7%, respectively. We subsequently evaluated a stepwise laboratory confirmation algorithm with detection of AFB as first-line method and IS2404 PCR performed only with those samples that were negative in microscopic analysis. This stepwise approach reduced unit cost by more than 50% to $5.41, and the total costs were reduced from $917 to $433.


Assuntos
Úlcera de Buruli/diagnóstico , Úlcera de Buruli/economia , Microscopia/economia , Reação em Cadeia da Polimerase/economia , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Biópsia por Agulha Fina , Úlcera de Buruli/tratamento farmacológico , Úlcera de Buruli/epidemiologia , Gana/epidemiologia , Custos de Cuidados de Saúde , Humanos , Microscopia/normas , Mycobacterium ulcerans/isolamento & purificação , Reação em Cadeia da Polimerase/normas , Rifampina/administração & dosagem , Rifampina/uso terapêutico , Sensibilidade e Especificidade , Estreptomicina/administração & dosagem , Estreptomicina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA